Crescent Biopharma Reports Q3 GAAP EPS of -$0.90 and Outlines Clinical Milestones
Crescent Biopharma (CBIO) has announced its third-quarter financial results, reporting a GAAP earnings per share (EPS) of -$0.90. Despite the net loss, the company remains focused on its clinical pipeline development and patient enrollment goals. The company stated it is currently on track to achieve multiple clinical data readouts in 2027. Additionally, management expects to have more than 2,000 patients dosed across its entire portfolio by mid-year, signaling continued progress in its clinical programs.
Tickers: $CBIO